Smart Radiotherapy Biomaterials for Cancer Therapy and Imaging

Dear Colleagues,

Cancer is the second cause of death worldwide in 2024, and one of the main reasons for its poor therapy is due to traditional treatment modalities such as chemotherapy, radiotherapy, and/or surgery. The associated toxicity related to the traditional treatment methods elicits many studies to be conducted preclinically evaluating the use of smart radiotherapy biomaterials in cancer treatment. The acclimation of smart biomaterials to the fluctuating physiological parameters and any outward tensions makes them compelling influencers on many aspects of homeopathic technology. Smart biomaterials can enhance promising treatments and boost the administration of long-lasting diseases, and they are applied in the fields of drug delivery systems, regenerative medicine, radiotherapy, medical gadgets, and immunotherapy. Preclinical studies have demonstrated many advantages, such as active targeting, long circulation, low immunogenicity, controlled drug release, and reduced toxicological effects in utilizing nanocarriers as targeted therapy for malignant tumors. Smart biomaterials can offer tissue-demonstrated precise modulation in the immunity of a cancer patient.

The goal of this Special Issue is to emphasize topical progress in research on applying smart radiotherapy biomaterials in cancer treatment and imaging. We encourage investigators and scientists to contribute original research and review articles underlining the latest applications of smart radiotherapy biomaterials in cancer treatment and imaging.

We look forward to receiving your contributions.

Dr. Kai Ding
Dr. Michele Moreau
Dr. Debarghya China
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.